Logo image of RGNX

REGENXBIO INC (RGNX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RGNX - US75901B1070 - Common Stock

14.97 USD
+0.38 (+2.6%)
Last: 12/22/2025, 4:30:02 PM
14.97 USD
0 (0%)
After Hours: 12/22/2025, 4:30:02 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to RGNX. RGNX was compared to 530 industry peers in the Biotechnology industry. RGNX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RGNX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RGNX had negative earnings in the past year.
In the past year RGNX has reported a negative cash flow from operations.
In the past 5 years RGNX reported 4 times negative net income.
RGNX had negative operating cash flow in 4 of the past 5 years.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

With a decent Return On Assets value of -33.88%, RGNX is doing good in the industry, outperforming 63.77% of the companies in the same industry.
RGNX has a Return On Equity of -110.20%. This is comparable to the rest of the industry: RGNX outperforms 43.77% of its industry peers.
Industry RankSector Rank
ROA -33.88%
ROE -110.2%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

RGNX has a Gross Margin of 87.18%. This is amongst the best in the industry. RGNX outperforms 89.43% of its industry peers.
In the last couple of years the Gross Margin of RGNX has declined.
RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
RGNX has more shares outstanding than it did 1 year ago.
RGNX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.80, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RGNX (-1.80) is comparable to the rest of the industry.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.8
ROIC/WACCN/A
WACC8.81%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.66 indicates that RGNX has no problem at all paying its short term obligations.
RGNX has a Current ratio of 2.66. This is in the lower half of the industry: RGNX underperforms 69.43% of its industry peers.
A Quick Ratio of 2.66 indicates that RGNX has no problem at all paying its short term obligations.
With a Quick ratio value of 2.66, RGNX is not doing good in the industry: 67.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.32%, which is quite impressive.
The Revenue has grown by 91.30% in the past year. This is a very strong growth!
RGNX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.81% yearly.
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%

3.2 Future

The Earnings Per Share is expected to grow by 16.45% on average over the next years. This is quite good.
The Revenue is expected to grow by 48.14% on average over the next years. This is a very strong growth
EPS Next Y32.24%
EPS Next 2Y18.09%
EPS Next 3Y17.77%
EPS Next 5Y16.45%
Revenue Next Year109.62%
Revenue Next 2Y76.41%
Revenue Next 3Y58.45%
Revenue Next 5Y48.14%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as RGNX's earnings are expected to grow with 17.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.09%
EPS Next 3Y17.77%

More info and screens

0

5. Dividend

5.1 Amount

RGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

REGENXBIO INC

NASDAQ:RGNX (12/22/2025, 4:30:02 PM)

After market: 14.97 0 (0%)

14.97

+0.38 (+2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners82.82%
Inst Owner Change-2.14%
Ins Owners7.13%
Ins Owner Change-2.88%
Market Cap757.78M
Revenue(TTM)161.32M
Net Income(TTM)-177.91M
Analysts84.21
Price Target32.09 (114.36%)
Short Float %11.66%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.56%
Min EPS beat(2)-22.99%
Max EPS beat(2)9.88%
EPS beat(4)2
Avg EPS beat(4)-18.77%
Min EPS beat(4)-75.63%
Max EPS beat(4)13.65%
EPS beat(8)3
Avg EPS beat(8)-8.87%
EPS beat(12)5
Avg EPS beat(12)-7.23%
EPS beat(16)6
Avg EPS beat(16)-6.26%
Revenue beat(2)1
Avg Revenue beat(2)-2.34%
Min Revenue beat(2)-25.51%
Max Revenue beat(2)20.83%
Revenue beat(4)1
Avg Revenue beat(4)-7.89%
Min Revenue beat(4)-25.51%
Max Revenue beat(4)20.83%
Revenue beat(8)2
Avg Revenue beat(8)-13.33%
Revenue beat(12)3
Avg Revenue beat(12)-16.53%
Revenue beat(16)5
Avg Revenue beat(16)-11.02%
PT rev (1m)0.74%
PT rev (3m)0.49%
EPS NQ rev (1m)-4.97%
EPS NQ rev (3m)-922.62%
EPS NY rev (1m)-19.57%
EPS NY rev (3m)-80.82%
Revenue NQ rev (1m)-6.93%
Revenue NQ rev (3m)-44.07%
Revenue NY rev (1m)-21.88%
Revenue NY rev (3m)-23.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.7
P/FCF N/A
P/OCF N/A
P/B 4.69
P/tB 4.69
EV/EBITDA N/A
EPS(TTM)-3.47
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-2.1
FCFYN/A
OCF(TTM)-2.04
OCFYN/A
SpS3.19
BVpS3.19
TBVpS3.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -33.88%
ROE -110.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.18%
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-26.5%
ROE(3y)-75.43%
ROE(5y)-47.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.45%
GM growth 5Y-4.88%
F-Score5
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.93%
Cap/Sales 1.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -1.8
F-Score5
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)103.5%
Cap/Depr(5y)301.57%
Cap/Sales(3y)13.73%
Cap/Sales(5y)15.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.56%
EPS Next Y32.24%
EPS Next 2Y18.09%
EPS Next 3Y17.77%
EPS Next 5Y16.45%
Revenue 1Y (TTM)91.3%
Revenue growth 3Y-43.83%
Revenue growth 5Y18.81%
Sales Q2Q%22.88%
Revenue Next Year109.62%
Revenue Next 2Y76.41%
Revenue Next 3Y58.45%
Revenue Next 5Y48.14%
EBIT growth 1Y36.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.6%
EBIT Next 3Y23.42%
EBIT Next 5Y18.75%
FCF growth 1Y54.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y52.4%
OCF growth 3YN/A
OCF growth 5YN/A

REGENXBIO INC / RGNX FAQ

What is the ChartMill fundamental rating of REGENXBIO INC (RGNX) stock?

ChartMill assigns a fundamental rating of 4 / 10 to RGNX.


Can you provide the valuation status for REGENXBIO INC?

ChartMill assigns a valuation rating of 0 / 10 to REGENXBIO INC (RGNX). This can be considered as Overvalued.


What is the profitability of RGNX stock?

REGENXBIO INC (RGNX) has a profitability rating of 2 / 10.


What is the expected EPS growth for REGENXBIO INC (RGNX) stock?

The Earnings per Share (EPS) of REGENXBIO INC (RGNX) is expected to grow by 32.24% in the next year.